Process for preparing benzene derivatives

专利摘要:
This invention provides benzene derivatives which are leukotriene antagonists, formulations of those derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.
公开号:SU1731042A3
申请号:SU884355477
申请日:1988-04-08
公开日:1992-04-30
发明作者:Дилейн Диллард Роберт；Элфрид Мккалла Дорис；Патрик Карр Фрэнсис
申请人:Эли Лилли Энд Компани (Фирма)；
IPC主号:

专利说明:

(L
WITH
The invention relates to biologically active substances, in particular to a method for producing benzene derivatives of the general formula
IT R, .o
-CH2-0-O-C-A-T12
where RI is ethyl or propyl;
R2 group —COOH or 5-tetrazolyl;
A - Ci-Sb-alkylidene with straight or branched chain,
which are leukotriene antagonists.
Known derivatives of benzene (A) of the general formula
IT RI
sn3-s: -yuo-sn2-snz,
chesky especially the common
(I)
silt;
 RazotAA) RI is hydrogen; Ct-Sat-alkyl, phenyl, are leukotriene antagonists. However, their activity is not high enough (see table).
The purpose of the invention is to develop a method for producing new benzene derivatives, which are more active leukotriene antagonists.
The goal is achieved by the fact that according to the method for producing benzene derivatives of the general formula, the benzene derivative of the general formula
OH R,
| / one
CHjCHg CHjX, (G,
where X is a suitable leaving group, such as halogen;
RI has the indicated meanings
h with
about
.N Yu

CJ
subjected to interaction with the compound of the General formula
ABOUT
HO- O} -C-A-R 2, (10
where R2 is a group-COO (Ci-O-alkyl), CN or 5-tetrazolyl,
and if R21 is -COO (C 1 - Landfill ohm), it is hydrolyzed to form compounds of formula I, where R2 is COOH, or, if R21 is CN, then it is reacted with an azide derivative to form a compound of formula I, where P2 is 5-tetrazolyl.
EXAMPLE 1. 4- (4-Acetyl-3-hydroxy-2-propenylphenyl) methoxy - y / oxobenzenebutanoic acid.
A. Preparation of 4- (4-methoxyphenyl) 4-oxobutanoic acid.
To a solution of 200 g of anisole in 2 liters of methylene chloride was added 278 g of succinic anhydride. The mixture is cooled with an external ice bath and 492.2 g of aluminum chloride is added in portions with stirring. The reaction mixture is kept cold for several hours and then allowed to warm to room temperature overnight.
The reaction mixture is poured into a mixture of ice and hydrochloric acid. The white precipitate formed is recovered by vacuum filtration. The solid is dried and then dissolved in 5N. sodium hydroxide solution. The solution is filtered and acidified with hydrochloric acid. The 06-developed precipitate is extracted with ethyl acetate. The layers are separated, the organic layer is dried over sodium sulfate / magnesium sulfate, filtered and evaporated in vacuo. The residue is crystallized from ethanol, giving 240.1 g of the subtitle intermediate indicated in the subtitle. T. pl. 142-144 ° C.
Calculated,%: C, 63.455; H 5.81.
C11H1204
Found,%: C 63.57; H 5.69.
B. Preparation of 4- (4-hydroxyphenyl) -4-oxobutanoic acid ethyl ester.
A mixture of 100 g of 4- (4-methoxyphenyl) 4-oxobutanoic acid, 500 ml of 48% hydrobromic acid and 100 ml of acetic acid is boiled under reflux for 36 hours.
The reaction mixture is concentrated in vacuo and ethanol is added.
Crystallization from a mixture of toluene and ethyl acetate 9: 1 yields 69.1 g of the subtitle intermediate. Mace spectrometry, PMR.
C. Preparation of 4- (4-acetyl-3-hydroxy-2-propylphenyl) meth-y-oxobenzenebutanoic acid ethyl ester.
1.38 g of metallic sodium was added to 200 ml of absolute ethanol. When the dissolution is complete, 16.6 g of the intermediate from Example 1B are added, followed by 11.4 g of 4-acetyl-3-hydroxy-2-propylbenzyl chloride and 7.5 g of sodium iodide. The reaction mixture is stirred under nitrogen for approximately 72 hours. This solution is poured into water and filtered. The solids are dried and get to 19.7 g of the target ester specified in the subtitle, So pl. 25-127 ° C. Mass spectrometry, PMR.
D, Preparation of 4- (4-acetyl-3-hydroxy-2-propylphenyl) methoxy-y-oxobenzenebutanoic acid.
To a mixture of 19.7 g of ester from the above Example 1C and 250 ml of ethanol was added 30 ml of 5N. sodium hydroxide solution. The mixture was heated under reflux for 2 hours, poured into water and acidified with concentrated hydrochloric acid. The resulting precipitate was recovered by vacuum filtration. 12.4 g are obtained by crystallization from ethanol.
target product specified in the header. Mp 175-176 ° C.
Calculated,%: C 68.74; H 6.29.
C22H2406
Found,%: C 68.96; H 6.07. The following substances are prepared from
corresponding phenols, following the procedure of example 1C (examples 2-4).
EXAMPLE 2 4- (4-Acetyl-3-hydroxy-2-propylphenyl) methoxy-Ј -oxobenzene hexanoic acid, ethyl ester. Yield 82%. M.p. 97-98 ° C.
Calculated,%: C 71.21; H 6.90.
S2BNZOOE
Found,%: C, 70.99; H 6.72. EXAMPLE 3 4- (4-Acetyl-3-hydroxy-2propylphenyl) methoxy-u3, / -dimethyl-b-sorbenzene-peptanoic acid, ethyl ester. Exit 63%. M.p. 74-78 ° C.
Calculated,%: C 71.34; H 7.54.
C27H3406
Found,%: C 71,22; H 7.63.
Example 4: 4- (4-Acetyl-3-hydroxy-2-propylphenyl) methoxy- (5-oxobenzene-pentaic acid, ethyl ether. Yield: 95%. Mp. 61-62 ° C.
Calculated,%: C, 70.40; H 7.09.
S2BNZOOE
Found,%: C 70.36; H7.11.
The following substances (examples 5 and 6) prepared from the corresponding esters of examples 2-4, according to the following procedure.
About 12.5 parts (w / v) of ethanol and about 1.5 parts (w / v) of 5N are added to the mixture from one part of the corresponding ester. sodium hydroxide. The mixture is heated under reflux for approximately 2 hours, poured into water and acidified with hydrochloric acid. The precipitate was separated by vacuum filtration and crystallization from ethanol.
EXAMPLE 5 4- (4-Acetyl-3-hydroxy-2-propylphenyl) methoxy - Ј-oxobenzene hexanoic acid. Yield 56%. M.p. 118-119 ° C.
Calculated,%: C 69.89; H 6.84.
C24H2806
Found,%: C 70.10; H 6.77.
EXAMPLE 6 4- (4-Acetyl-3-hydroxy-2-propylphenyl) methoxy - / e, / dimethyl-d - okogen-penpentanoic acid. Yield 13%. M.p. 99-100 ° C.
Calculated,%: C, 70.40; H 7.09.
SubNZOE
Found,%: C 70.67; H 7.20.
Example. 1- (4) 4-Acetyl-3-hydroxy-2-propylphenyl (methoxy) phenyl -2- (1H-tetrazol-5-yl) ethanone.
A. Preparation of 4- (4-acetyl-3-hydroxy-2-propylphenyl) methoxy benzoic acid, ethyl ester.
Following the procedure of Example 1C, 2.9 g of 4-acetyl-3-hydroxy-2-propylbenzyl chloride and 4.5 g of ethyl 4-hydroxybenzoic acid ester are reacted to yield 4.6 g of the intermediate compound. M.p. 70-72 ° C.
Calculated,%: C, 70.76; H 6.78.
C21H2405
Found,%: C 69.98; H 6.78.
B. Preparation of 4- (4-acetyl-3-hydroxy-2-propylphenyl) methoxy - / -oxobenzene-propionitrile.
0.48 g of metallic sodium and a trace amount of iron (III) chloride are added to 250 ml of liquefied ammonia at a temperature of about -30 ° C. Under nitrogen, 3.0 g of acetonitrile and 2.5 g of ester from example 8A are added in 25 ml of diethyl ether. After stirring for 3 hours at room temperature, diethyl ether was added and the ammonia was allowed to evaporate. Water is added and the layers are separated. The aqueous layer is acidified and extracted with ethyl acetate. The ethyl acetate layers were combined, dried over sodium sulfate, and
concentrated in vacuo. The residue is purified by high-pressure liquid chromatography on silica gel, which is eluted with a 9: 1 mixture of toluene and ethyl acetate. The appropriate fractions are combined and evaporated, yielding 0.4 g of the desired nitrile indicated in the subtitle. M.p. 164-166 ° C.
Calculated,%: C, 72.84; H 6.24; N 4.14.
C21H21N04
Found,%: C 73.58; H 5.64; N 3.73. C. Preparation of 1- (4-X4-acetyl-3-hydroxy-2-propylphenyl (methoxy) phenyl -2- (1H) -tetrazol-5-yl) ethanone.
A mixture of 2 g of nitrile from Example 8B and 6.6 g of tri-n-butyltin azide are refluxed for 4 days in 1,2-dimethoxyethane. After cooling, the reaction mixture is poured into a mixture of 150 ice and
50 ml of hydrochloric acid. After stirring for 1 hour, the precipitate formed is recovered by lteration. The solid is dissolved in ethyl acetate. Crystallization is initiated by the addition of hexane. and after cooling for several days, the crystals formed are isolated by filtration to obtain 1.0 g of the title product. M.p. 207-209 ° C.
Calculated,%: C 63.94; H 5.62; N 14.21.
C21H22N404
 Found,%: C 64.35; H 5.51; N 14.00.
The following tetrazoles (Examples 8-17) were obtained from the corresponding nitrile intermediates according to the procedure of the example of CS.
Try on 1- (4) 4-Acetyl-3-hydroxy-2-propylphenyl (methoxy) phenyl-3- (1 H-tetrazol-5-yl) -1-propanone. Yield 16%. M.p. 206-208 ° C.
Calculated,%: C 64.69; H 5.92; N 13.72.
C22H24N404
Found,%: C 64.78; H 5.89; N 13.51. EXAMPLE 9 1- (4-) 4-Acetyl-3-hydroxy-2-propylphenyl (methoxy) phenyl-4- (1 H-tetr-azol-5-yl) -1-butanone. Yield 56%. T.pl. 178-180 ° C.
Calculated,%: C, 65.39; H 6.20; N 13.26.
C23H26N404
Found,%; C 65.59; H 6.10: N 13.43.
An example. 1- (4-) 4-Acetyl-3-hydroxy-2-propylphenyl (methoxy) phenyl-5- (1H-tetrazol-5-yl) -1-pentanone. Yield 51%. M.p. 163-166 ° C.
Calculated,%: C 66.04; H 6.47: N 12.84.
C24H28N404
Found,%; C 66.29; H 6.34; N 12.64. EXAMPLE 11 1- (4-) 4-Acetyl-3-hydroxy-2-propylphenyl (mitoxy) -2-hydroxyphenyl-4- (1 H-tetrazol-5-yl) -1- butanone. Exit 32%. T.pl. 170-174 ° C.
Calculated,%: C 63.00; H 5.98; N 12.78.
C23H21N405
Found,%: C 63.04; H 6.22; N 12.55.
EXAMPLE 12 1- (4-) 4-Acetyl-3-hydroxy-2-propylphenyl (methoxy) phenyl -2-methyyl-3- (1 H-tetrazol-5-yl) -1-propanone. Yield 41%. T.pl. 140-142 ° C.
Calculated,%; C 65.39; H 6.20; N 13.26.
C23H26N404
Found,%: C 65.56; H 6.03; N 12.98.
EXAMPLE 13 1- (4-) 4-Acetyl-3-hydroxy-2-propylphenyl (methoxy) phenyl-3,3-di-methyl-4 (1 H-tetrazol-5-yl ) -1-butanone. Yield 35%. M.p. 151-153 ° C.
Calculated,%: C 66.65; H 6.71; N 12.44.
C25H30N4CM
Found,%: C 66.79; H 6.85; N 12.26.
Example 14 1- (4-) 4-Acetyl-3-hydroxy-2-ethylphenyl (methoxy) phenyl-3.3-dime-tyl-4- (1 H-tetrazol-5-yl) -1-butanone. Yield 41%. M.p. 121-123 ° C.
Calculated,%: C 66.04; H 6.48; N 12.84.
C24H28N404
Found,%: C 66.62; H 6.72; N 12.51.
EXAMPLE 15 1- (3-) 4-Acetyl-3-hydroxy-2-propylphenyl (methoxy) phenyl-4- (1H-tetrazol-5-yl) -1-butanone. Yield 57%. M.p. 140-145 ° C.
Calculated,%: C, 65.39; H 6.20; N 13.26.
C23H26N404
Found,%: C 65,17; H 6.59; N 12.97.
The following substances were obtained by hydrolysis of the corresponding esters in accordance with the method of example 10.
16. 4- (4-Acetyl-2-ethyl-3-hydroxyphenyl) methoxy -,, / -dimethyl - y-hydroxybenzene-pentanoic acid. Yield 80%. M.p. 120-122 ° C.
Calculated,%: C 69.89; H 6.84.
C24H2806
Found,%: C 69.79; H 6.94.
Example 17 1 - (2 -) - 4- (4-Acetyl-3-hydroxy-2-propylphenyl) -methoxy (phenyl) -2-o-x-ethyl cyclopentenacetic acid. Yield 61%. M.p. 103-104 ° C.
Calculated,%: C 71.66; H 7.13.
C27H3206
Found,%: C 71.76; H 7.34.
The following carboxylic acids are prepared from the corresponding esters, following the procedure of Example 1D.
EXAMPLE 18 6- (4-Acetyl-3-hydroxy-2-propylphenyl) methoxy -1,2,3,4-tetrahydr-o-1-oxo-2-naphthalene acetic acid. Yield 43%. M.p. 147-149 ° C.
The substances of the formula I are potentially useful for the treatment of any
conditions, including clinical conditions, which are characterized by an excessive release of C4, D4 and E4 leukotrienes. These conditions include hypersensitive
immediate type reactions such as asthma. The substances described in the invention should also alleviate some of the symptoms of chronic bronchitis and fibrosis of the bladder, and possibly rheumatoid arthritis, due to their ability to antagonize leukotrienes. These substances are also useful for inhibiting the cardiovascular effects of leukotrienes, thereby ensuring their
5 efficacy for treating conditions such as shock and ischemic heart disease.
The term excess secretion of leukotrienes refers to that amount
0 leukotrienes, which is sufficient to cause a specific condition associated with such an amount. The amount of leukotrienes, which is redundant, depends on a variety of factors, including the specific type of leukotrienes involved, the amount of leukotrienes necessary to cause a particular condition, and the type of mammal. In this area of medicine, the success of treating mammals suffering from
0 or susceptible to a condition characterized by excessive excretion of leukotrienes, using substances of formula I can be measured by returning to the initial state or preventing symptoms
5 of this state. The bicyclic compounds of this invention provide an exceptionally high blood level.
Antagonism of leukotrienes is demonstrated using the following procedure.
0 test.
Male Guinea Pigs Hartley weighing 200-450 g are slaughtered by decapitation. The lower intestinal section is removed, the cavity is cleaned and the tissues are separated.
5 into 2.5 cm segments. Intestinal tissues are placed in tissue baths (volume 10 ml), which contain Krebs bicarbonate solution of the following composition, mol / l: 4.6 KCI, 1,2-dihydrate calcium chloride, 1.2 potassium dihydrogenofhosphate, magnesium sulfate 1,2-heptahydrate, sodium chloride, 118.2 sodium hydrogencarbonate 24.8 and 10.0 dextrose. The temperature of the solution in the bath support equal to 37 ° C. It is aerated with a mixture of 95% oxygen.
5 and 5% carbon dioxide. In addition, the buffer solution contains 1 µmol / L atropine to reduce the spontaneous activity of intestinal tissues. Isometric measurements were made with a force transducer — a movement of Grass EF-03-C,
moreover, the force was recorded by the multichannel recorder F. Grass as a change in the force, a passive force of 0.5 g was applied to the tissues. After an appropriate period of equilibration, separate sub-maximal control responses to pure LTD4 were obtained. After a five minute exposure of the intestinal tissues with the experimental medicament, the LTD4 control concentration is added to the tissue bath. The response of intestinal tissue to LTD4 in the presence of a drug is compared to the response in the absence of a drug. Different degrees of LTD4 antagonism were obtained using 2–4 different concentrations of experimental substances on individual intestinal tissues. From this data, using an interpolation linear regression, found the antagonist concentration, which provides 50% inhibition of LTD4 responses (log ICso) (50% inhibition concentration).
The tests of the substances of formula I in these two methods are summarized in the table.
The proposed method allows to obtain new benzene derivatives, which are more active leukotriene antagonists (see table).

权利要求:
Claims (1)
[1]
Invention Formula
Method for preparing benzene derivatives of general formula I
Inhibition of LTD4 (%) caused by intestinal contractions
IT RIo
CH3-C- (O / -CH2-0-5} -c: -A-R2
where RI is ethyl or propyl;
R2 is a -COOH or 5-tetrazolyl group; A - Ci-Sb-alkylidene with straight or branched chain,
characterized in that the benzene derivative of general formula II
UN RI SNSSH
where X is a suitable leaving group, such as halogen;
RI has the indicated meanings, is reacted with a compound of general formula III
V /
HO - @ - 4-A-Rf,
where Ra is a -COO group (Ci-Cl-alkyl), CN or 5-tetrazolyl, and if R2 is -COO (C1-C4-alkyl), it is hydrolyzed to form compounds of general formula I, where R2 is COOH , or, if R2 is CN, then it is reacted with an azide derivative to obtain compounds of general formula I. where R2 is 5-tetrazolyl.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP5048017B2|2012-10-17|Substituted phenylalkanoic acid derivatives and uses thereof

---

SU1750420A3|1992-07-23|Method of benzene derivatives synthesis

---

EP0438869B1|1994-12-14|Improvements in and relating to angiotensin II antagonists

---

USRE40667E1|2009-03-17|[R-|]-2-|-β,δ-dihydroxy-5-|carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof

---

CA2415847C|2011-09-27|Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same

---

SU1731042A3|1992-04-30|Process for preparing benzene derivatives

---

US4725676A|1988-02-16|5-|-2-hydroxybenzene-acetic acids and salts and lactones thereof having a potentially inhibitory effect on 15-hydroxy-prostaglandin dehydrogenase

---

JP2004506728A|2004-03-04|Aminoalkoxybenzoyl-benzofuran or benzothiophene derivative, method for producing the same, and composition containing the same

---

SU1635899A3|1991-03-15|Process for preparing 3-[|methyl]-2- oxybenzene methanols

---

LU83183A1|1981-06-24|NOVEL CLASS OF ACYLATED CARNITINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC USE

---

CN108484598B|2021-03-02|Indolizine derivative and application thereof in medicine

---

US4820723A|1989-04-11|Disubstituted tetrazole leukotriene antagonists and methods for their use thereas

---

EP0142754A2|1985-05-29|2-Substituted-benzoic acid imidazoles, process for preparing them and pharmaceutical compositions containing them

---

US5362879A|1994-11-08|4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation

---

EP1773782A1|2007-04-18|Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents

---

US4906757A|1990-03-06|Process for the preparation of dextrorotatory 3-|-1H,3H-pyrrolo [1,2-c]-7-thiazolecarboxylic acid

---

US4783473A|1988-11-08|Geminally substituted cyclic ether carboxylic acids, derivatives thereof, compositions containing same and method of use

---

US4820722A|1989-04-11|Disubstituted tetrazoles and their use as leukotriene antagonists

---

US5705525A|1998-01-06|Thiophene compounds

---

US4057544A|1977-11-08|α-Alkylsulfobenzyl penicillins

---

US4562287A|1985-12-31|2-|-4-hexenoic acid and derivatives thereof having anti-inflammatory activity

---

JP2004506726A|2004-03-04|Aminoalkenylbenzoyl-benzofuran or benzothiophene derivative, method for producing the same and composition containing the same

---

US3872112A|1975-03-18|Tetrahydrofurfuryl aminoesters

---

US5177219A|1993-01-05|N-phenyl-N'-thienylmethyl-bis-diamino-5-methylene-1,3-dioxane-4,6-dione compounds

---

JP2000290259A|2000-10-17|Production of optically active imidazole compound and it synthetic intermediate

同族专利:

---

公开号 | 公开日

---

DE3872576D1|1992-08-13|

---

DE3872576T2|1993-03-04|

---

HU203517B|1991-08-28|

---

KR880012520A|1988-11-28|

---

JPS63277642A|1988-11-15|

---

CN88101939A|1988-12-14|

---

EP0288190A1|1988-10-26|

---

DK188388D0|1988-04-07|

---

EP0288190B1|1992-07-08|

---

EG18480A|1993-04-30|

---

NZ224137A|1991-01-29|

---

PT87180A|1988-05-01|

---

AU1433488A|1988-10-27|

---

ZA882420B|1989-12-27|

---

GR3005836T3|1993-06-07|

---

HUT54338A|1991-02-28|

---

DK188388A|1989-01-12|

---

ES2041791T3|1993-12-01|

---

AU608311B2|1991-03-28|

---

CA1327588C|1994-03-08|

---

AT78023T|1992-07-15|

---

IE61277B1|1994-10-19|

---

IE881060L|1988-10-10|

---

PH25349A|1991-05-13|

---

US4874777A|1989-10-17|

---

PT87180B|1992-07-31|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

SU469247A3|1972-01-14|1975-04-30|Майлз Лабораториз Инк |The method of obtaining chromone derivatives|

---

AT14579T|1979-03-20|1985-08-15|Fisons Plc|PHARMACEUTICAL HETEROCYCLIC COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND COMPOSITIONS CONTAINING THE SAME.|

---

NZ194844A|1979-09-05|1983-07-29|Glaxo Group Ltd|Phenoxyalkoxyphenyl derivatives and pharmaceutical compositions|

---

EP0056172B1|1981-01-09|1985-04-03|FISONS plc|Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them|

---

DE3265715D1|1981-03-24|1985-10-03|Fisons Plc|Anti srs-a carboxylic acid derivatives, processes for their production and pharmaceutical formulations containing them|

---

US4474788A|1981-11-12|1984-10-02|Fisons Plc|Anti-SRSA quinoline carboxylic acid derivatives|

---

US4499299A|1981-12-30|1985-02-12|Ici Americas Inc.|Pharmaceutically active phenylcarboxylic acid derivatives|

---

US4661505A|1982-11-03|1987-04-28|Eli Lilly And Company|Leukotriene antagonists|

---

ZA844519B|1983-06-24|1985-02-27|Hoffmann La Roche|Dihydrobenzopyran derivatives|

---

US5105017A|1983-07-18|1992-04-14|Eli Lilly And Company|Leukotriene antagonist intermediates|

---

US4644071A|1984-07-11|1987-02-17|G. D. Searle & Co.|Aralkoxy and aryloxyalkoxy kojic acid derivatives|

---

US4617407A|1984-08-30|1986-10-14|Merck Frosst Canada, Inc.|Leukotriene antagonists|

---

US4567279A|1984-12-13|1986-01-28|Usv Pharmaceutical Corp.|Diarylhydroxy alkanones and alkenones antiallergy agents|

---

US4628115A|1985-03-25|1986-12-09|Hoffmann-La Roche Inc.|Substituted 4-acetyl-3-hydroxyphenoxy alkanoic acids|

---

PT85110A|1986-06-23|1987-07-01|Merck Frosst Canada Inc|Process for preparing benzenealkanoic acid derivatives useful as leukotriene antagonists|US4853398A|1987-04-13|1989-08-01|Eli Lilly And Company|Leukotriene antagonists and use thereas|

---

NZ229761A|1988-07-12|1991-10-25|Ici Pharma|Substituted thiazole derivatives for use as inhibitors of enzyme 5-lipoxygenase; pharmaceutical compositions and preparatory processes|

---

PH30449A|1991-11-25|1997-05-28|Lilly Co Eli|Substituted phenyl phenol leukotriene antagonists|

---

CN101444496B|2001-06-12|2011-04-13|维尔斯达医疗公司|Compounds for the treatment of metabolic disorders|

---

AU2009243028B2|2008-04-30|2015-01-29|Wellstat Therapeutics Corporation|Tetrazole compounds for reducing uric acid|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US07/037,284|US4874777A|1987-04-10|1987-04-10|Leukotriene antagonists|

---